DK1818059T3 - Forebyggende eller terapeutisk middel mod glaucoma - Google Patents

Forebyggende eller terapeutisk middel mod glaucoma

Info

Publication number
DK1818059T3
DK1818059T3 DK05819681T DK05819681T DK1818059T3 DK 1818059 T3 DK1818059 T3 DK 1818059T3 DK 05819681 T DK05819681 T DK 05819681T DK 05819681 T DK05819681 T DK 05819681T DK 1818059 T3 DK1818059 T3 DK 1818059T3
Authority
DK
Denmark
Prior art keywords
glaucoma
therapeutic agent
preventive
salt
preventing
Prior art date
Application number
DK05819681T
Other languages
English (en)
Inventor
Makoto Kanebako
Shin Sugimoto
Masatoshi Takahashi
Ken Mizuno
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Application granted granted Critical
Publication of DK1818059T3 publication Critical patent/DK1818059T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK05819681T 2004-12-23 2005-12-22 Forebyggende eller terapeutisk middel mod glaucoma DK1818059T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63811804P 2004-12-23 2004-12-23
PCT/JP2005/023570 WO2006068208A1 (ja) 2004-12-23 2005-12-22 緑内障予防又は治療剤

Publications (1)

Publication Number Publication Date
DK1818059T3 true DK1818059T3 (da) 2009-03-16

Family

ID=36601805

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05819681T DK1818059T3 (da) 2004-12-23 2005-12-22 Forebyggende eller terapeutisk middel mod glaucoma

Country Status (24)

Country Link
EP (1) EP1818059B1 (da)
JP (1) JP4099201B2 (da)
KR (1) KR101286813B1 (da)
CN (1) CN101087613B (da)
AT (1) ATE415972T1 (da)
AU (1) AU2005320085B2 (da)
BR (1) BRPI0519007A2 (da)
CA (1) CA2585372A1 (da)
CY (1) CY1108651T1 (da)
DE (1) DE602005011476D1 (da)
DK (1) DK1818059T3 (da)
EA (1) EA011085B1 (da)
ES (1) ES2317338T3 (da)
HK (1) HK1113312A1 (da)
MX (1) MX2007007614A (da)
MY (1) MY138811A (da)
NO (1) NO20072187L (da)
NZ (1) NZ555137A (da)
PL (1) PL1818059T3 (da)
PT (1) PT1818059E (da)
SI (1) SI1818059T1 (da)
TW (1) TWI367098B (da)
WO (1) WO2006068208A1 (da)
ZA (1) ZA200704874B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007007879A1 (ja) * 2005-07-14 2007-01-18 Sharp Kabushiki Kaisha 表示素子、及びこれを用いた電気機器
EP2319514A4 (en) 2008-07-25 2011-11-02 Asahi Kasei Pharma Corp STABLE AQUEOUS SOLUTION COMPOSITION COMPRISING A SULFONAMIDE COMPOUND
ES2684351T3 (es) * 2011-02-04 2018-10-02 Kowa Co., Ltd. Terapia farmacológica para prevenir o tratar glaucoma
EA026904B1 (ru) * 2012-11-23 2017-05-31 Игорь Михайлович Юхт Способ количественного определения полигексаметиленбигуанидина (пгмб) гидрохлорида в составах для приготовления жидких лекарственных средств для лечения заболеваний глаз и носа (2 варианта)
US20160339018A1 (en) * 2013-04-24 2016-11-24 Kyushu University, National University Corporation Therapeutic agent for ocular fundus disease
EP3199162B1 (en) * 2014-09-25 2022-03-09 Kowa Company, Ltd. Pharmaceutical product
HUE048790T2 (hu) * 2014-09-25 2020-09-28 Kowa Co Vizes készítmény
WO2016093344A1 (ja) 2014-12-12 2016-06-16 興和株式会社 新規水性組成物
TWI699205B (zh) * 2014-12-12 2020-07-21 日商興和股份有限公司 用於預防或治療青光眼之藥物療法
KR20160108121A (ko) 2015-03-06 2016-09-19 코와 가부시키가이샤 수성 조성물
JP2018118905A (ja) * 2015-04-27 2018-08-02 恵 本庄 白内障術後合併症の予防治療剤
CN106310285A (zh) * 2015-06-15 2017-01-11 江苏吉贝尔药业股份有限公司 一种新的盐酸利舒地尔滴眼液及其制备方法
JP6886322B2 (ja) * 2016-03-25 2021-06-16 興和株式会社 眼科用組成物
CN107164328A (zh) * 2017-06-30 2017-09-15 太仓卡斯特姆新材料有限公司 一种高稳定性mcf‑7乳腺癌细胞的复苏方法
EP4338751A3 (en) 2017-12-21 2024-05-22 Santen Pharmaceutical Co., Ltd. Medicament comprising combination of sepetaprost and rho-associated coiled-coil containing protein kinase inhibitor
JP2024503021A (ja) 2021-01-11 2024-01-24 インサイト・コーポレイション Ｊａｋ経路阻害剤及びｒｏｃｋ阻害剤を含む併用療法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9401108D0 (sv) * 1994-03-31 1994-03-31 Leiras Oy Ophthalmic composition I
DE19512639A1 (de) * 1995-04-05 1996-10-10 Merck Patent Gmbh Benzonitrile und -fluoride
AU720326B2 (en) * 1995-12-21 2000-05-25 Alcon Laboratories, Inc. Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia
JPH10310576A (ja) * 1997-03-10 1998-11-24 Hiroyoshi Hidaka イソキノリンスルフォンアミド誘導体及びこれを有効成分とする医薬
KR100390612B1 (ko) * 1997-04-25 2003-07-07 화이자 인코포레이티드 타입 5 시클릭 구아노신 3',5'-모노포스페이트포스포디에스테라제를 억제하는 성기능 장애 치료용피라졸로피리미디논 제조용 중간체의 제조 방법
FR2777189B1 (fr) 1998-04-09 2001-04-06 Chauvin Lab Sa Composition ophtalmique comprenant un beta-bloquant
EP1074545A4 (en) * 1998-04-23 2001-08-22 Hiroyoshi Hidaka ISOCHINOLINE SULPHONAMIDE DERIVATIVES AND MEDICINES CONTAINING IT AS AN ACTIVE INGREDIENT
JP4212149B2 (ja) * 1998-06-11 2009-01-21 株式会社デ・ウエスタン・セラピテクス研究所 医薬
AU5198199A (en) 1998-08-17 2000-03-06 Senju Pharmaceutical Co., Ltd. Preventives/remedies for glaucoma
ATE286021T1 (de) * 1998-10-22 2005-01-15 Neurosearch As Substituierte phenylderivate, ihre herstellung und verwendung

Also Published As

Publication number Publication date
AU2005320085A1 (en) 2006-06-29
WO2006068208A1 (ja) 2006-06-29
EP1818059B1 (en) 2008-12-03
ES2317338T3 (es) 2009-04-16
CN101087613B (zh) 2010-08-18
EA011085B1 (ru) 2008-12-30
EP1818059A1 (en) 2007-08-15
CY1108651T1 (el) 2014-04-09
EP1818059A4 (en) 2007-12-26
HK1113312A1 (en) 2008-10-03
SI1818059T1 (sl) 2009-04-30
AU2005320085B2 (en) 2010-07-29
CA2585372A1 (en) 2006-06-29
KR20070090897A (ko) 2007-09-06
BRPI0519007A2 (pt) 2008-12-23
ATE415972T1 (de) 2008-12-15
NO20072187L (no) 2007-07-13
TW200628160A (en) 2006-08-16
NZ555137A (en) 2009-10-30
JPWO2006068208A1 (ja) 2008-06-12
ZA200704874B (en) 2008-08-27
PL1818059T3 (pl) 2009-05-29
TWI367098B (en) 2012-07-01
KR101286813B1 (ko) 2013-07-17
MY138811A (en) 2009-07-31
PT1818059E (pt) 2008-12-31
EA200701134A1 (ru) 2007-10-26
DE602005011476D1 (de) 2009-01-15
JP4099201B2 (ja) 2008-06-11
MX2007007614A (es) 2007-08-15
CN101087613A (zh) 2007-12-12

Similar Documents

Publication Publication Date Title
DK1818059T3 (da) Forebyggende eller terapeutisk middel mod glaucoma
WO2003092584A3 (en) Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
WO2007076360A8 (en) (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
ATE527993T1 (de) Verbindung zur vorbeugung und behandlung von augen-asthenopie und pseudomyopie
WO2008052081A8 (en) Photochemical therapy to affect mechanical and/or chemical properties of body tissue
WO2006068829A9 (en) Agents which regulate, inhibit, or modulate the activity and/or expression of lysyl oxidase (lox) and lox-like proteases as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
WO2007076367A3 (en) Rnai-mediated inhibition of rho kinase for treatment of ocular hypertension / glaucoma
WO2007126364A3 (en) Use of antisecretory factors for treating intraocular hypertension
HK1102913A1 (en) Statins for the treatment of ocular hypertension and glaucoma
WO2004069181A3 (en) Composition for the treatment of intraocular pressure
WO2007047242A3 (en) Ophthalmic surgical irrigating solutions containing hyaluronidase
EP1752158A4 (en) CORNEAL NEURITOGENESIS PROMOTER CONTAINING PACAP AND ITS DERIVATIVE
WO2005027884A3 (en) Stabilized ocular solutions
WO2007127711A3 (en) Abnormal cannabidiols as agents for lowering intraocular pressure
MXPA04001255A (es) Uso de compuesto para el tratamiento de condiciones que resultan de lesion al nervio corneo despues de lasik y otras cirugias oculares o trauma.
TW200806284A (en) Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma
WO2009031575A1 (ja) リチウム塩を有効成分として含有する後眼部疾患の治療又は予防剤
WO2007024860A3 (en) Sulfonamides
WO2002060339A3 (en) Ophthalmic compositions for treating ocular hypertension
RU2007104148A (ru) Способ коррекции зрения после хирургических операций, выполненных на роговой оболочке глаза
UA37634A (uk) Спосіб хірургічного лікування відшарувань сітківки з гігантськими розривами
WO2007118017A3 (en) Method for preventing increases in postoperative intraocular pressure